Home » Stocks » MNOV

MediciNova, Inc. (MNOV)

Stock Price: $5.43 USD 0.11 (2.07%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $5.77 +0.34 (6.26%) Mar 5, 7:07 PM
Market Cap 264.34M
Revenue (ttm) n/a
Net Income (ttm) -13.85M
Shares Out 44.41M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $5.43
Previous Close $5.32
Change ($) 0.11
Change (%) 2.07%
Day's Open 5.25
Day's Range 5.23 - 5.43
Day's Volume 104,928
52-Week Range 2.79 - 13.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 days ago

LA JOLLA, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exc...

GlobeNewsWire - 1 month ago

LA JOLLA, Calif., Jan. 31, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exch...

GlobeNewsWire - 1 month ago

LA JOLLA, Calif., Jan. 18, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exch...

GlobeNewsWire - 1 month ago

LA JOLLA, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exch...

GlobeNewsWire - 2 months ago

LA JOLLA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exch...

GlobeNewsWire - 2 months ago

LA JOLLA, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exch...

GlobeNewsWire - 3 months ago

LA JOLLA, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exch...

GlobeNewsWire - 3 months ago

LA JOLLA, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exch...

GlobeNewsWire - 3 months ago

LA JOLLA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exch...

GlobeNewsWire - 4 months ago

LA JOLLA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exch...

GlobeNewsWire - 4 months ago

LA JOLLA, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exc...

GlobeNewsWire - 4 months ago

LA JOLLA, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exch...

GlobeNewsWire - 5 months ago

LA JOLLA, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock E...

24/7 Wall Street - 5 months ago

MediciNova Inc. (NASDAQ: MNOV) has announced progress in its COVID-19 vaccine prototype, which stands out from the rest as it is administered intranasally.

GlobeNewsWire - 5 months ago

LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock E...

GlobeNewsWire - 5 months ago

LA JOLLA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock E...

GlobeNewsWire - 6 months ago

New information for Spike protein specific antibody response after a single intranasal dose New information for Spike protein specific antibody response after a single intranasal dose

GlobeNewsWire - 7 months ago

LA JOLLA, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Ex...

GlobeNewsWire - 7 months ago

LA JOLLA, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Ex...

24/7 Wall Street - 7 months ago

MediciNova Inc. (NASDAQ: MNOV) saw the coronavirus bump on Monday after the company joined the list of COVID-19 stocks.

Benzinga - 7 months ago

MediciNova (NASDAQ: MNOV) shares are trading higher on Monday after the company announced an agreement with BioComoor for the joint development of a SARS-CoV-2 vaccine.

The Motley Fool - 7 months ago

The small-cap pharmaceutical company announced a collaboration to develop a coronavirus vaccine.

GlobeNewsWire - 7 months ago

LA JOLLA, Calif., July 27, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Ex...

GlobeNewsWire - 7 months ago

LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock E...

GlobeNewsWire - 8 months ago

LA JOLLA, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock E...

GlobeNewsWire - 8 months ago

LA JOLLA, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Ex...

GlobeNewsWire - 8 months ago

LA JOLLA, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Ex...

GlobeNewsWire - 10 months ago

LA JOLLA, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock E...

GlobeNewsWire - 10 months ago

LA JOLLA, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock E...

GlobeNewsWire - 11 months ago

LA JOLLA, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock E...

GlobeNewsWire - 1 year ago

LA JOLLA, Calif., Feb. 17, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Ex...

GlobeNewsWire - 1 year ago

LA JOLLA, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Ex...

GlobeNewsWire - 1 year ago

LA JOLLA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Ex...

GlobeNewsWire - 1 year ago

LA JOLLA, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Ex...

GlobeNewsWire - 1 year ago

LA JOLLA, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Ex...

GlobeNewsWire - 1 year ago

LA JOLLA, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Ex...

GlobeNewsWire - 1 year ago

LA JOLLA, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock E...

GlobeNewsWire - 1 year ago

LA JOLLA, Calif., Sept. 11, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock E...

GlobeNewsWire - 1 year ago

LA JOLLA, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Ex...

Seeking Alpha - 1 year ago

MNOV has very strong phase 2b results in a subtype of MS for its lead candidate.

About MNOV

MediciNova, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its ... [Read more...]

Industry
Biotechnology
IPO Date
Feb 8, 2005
CEO
Dr. Yuichi Iwaki
Employees
9
Stock Exchange
NASDAQ
Ticker Symbol
MNOV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for MediciNova stock is "Strong Buy." The 12-month stock price forecast is 18.50, which is an increase of 240.70% from the latest price.

Price Target
$18.50
(240.70% upside)
Analyst Consensus: Strong Buy